Modality
Fusion Protein
MOA
PD-1i
Target
TYK2
Pathway
PI3K/AKT
PTSDFSGSFL
Development Pipeline
Preclinical
Dec 2018
→ Sep 2028
PreclinicalCurrent
NCT08277286
2,879 pts·FSGS
2018-12→2028-09·Recruiting
2,879 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-112.5y awayInterim· FSGS
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2028-09-11 · 2.5y away
FSGS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08277286 | Preclinical | FSGS | Recruiting | 2879 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| RAR-1117 | Ultragenyx | Phase 1/2 | TYK2 | |
| Datocilimab | Neumora | Phase 1 | TYK2 |